U.S. Food and Drug Administration Grants Breakthrough Therapy Designation for Adaptimmune’s Affinity Enhanced T-cell Therapy Targeting NY-ESO in Synovial Sarcoma

9 February 2016

Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for the company’s affinity enhanced T-cell therapy targeting NY-ESO in synovial sarcoma for HLA-A*201, HLA-A*205 or HLA-A*206 allele-positive patients with inoperable or metastatic synovial sarcoma who have received prior chemotherapy and whose tumor expresses the NY-ESO-1 tumor antigen.

“We are committed to investigating the potential of our NY-ESO-1-T cell therapy across a variety of cancers. We are pleased that the FDA has granted Breakthrough Therapy designation for our T-cell therapy in synovial sarcoma, recognizing both the unmet need for patients suffering from this disease as well as the promise of these early data,” said Dr. Rafael Amado, Adaptimmune’s Chief Medical Officer. “We look forward to working closely with the FDA to expedite the clinical development of this therapeutic candidate.”

Please click on the link below to download the full Press Release:-

U.S. Food and Drug Administration Grants Breakthrough Therapy Designation for Adaptimmune’s Affinity Enhanced T-cell Therapy Targeting NY-ESO in Synovial Sarcoma

Adaptimmune to Participate in Two Upcoming Investor Conferences

3 February 2016

Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that James Noble, Chief Executive Officer of Adaptimmune, will present at the following two conferences, both being held at the Waldorf Astoria in New York City:

  • The 2016 BIO CEO & Investor Conference on Tuesday February 9, 2016 at 9:00AM ET (2:00 PM GMT); and
  • The Leerink Partners 5th Annual Global Healthcare Conference on Wednesday February 10, at 8:25 AM ET (1:25 PM GMT).

Adaptimmune’s presentations will be webcast live for investors through the investor section of www.adaptimmune.com and available for a period of 30 days following the conference.

Please click on the link below to download the full Press Release:-

Adaptimmune to Participate in Two Upcoming Investor Conferences

Adaptimmune and GSK expand Strategic Immunotherapy Collaboration

2 February 2016

Adaptimmune Therapeutics plc and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the companies have expanded the terms of their strategic collaboration agreement to accelerate Adaptimmune’s lead clinical cancer program, an affinity enhanced T-cell immunotherapy (GSK3377794) targeting NY-ESO-1, toward pivotal trials in synovial sarcoma.

Please click on the link below to download the full Press Release:-

Adaptimmune and GSK expand Strategic Immunotherapy Collaboration

 

Adaptimmune Announces New Additions to Manufacturing Senior Management

22 January 2016

Adaptimmune Therapeutics plc (NASDAQ: ADAP), today announced that it has augmented its manufacturing leadership to prepare for clinical and commercial scale up with the additions of William Buecheler as Vice President, Manufacturing Operations, and Phil Bassett as Head of Process Development.

Mr. Buecheler is responsible for Adaptimmune’s global manufacturing operations, including contract and in-house manufacturing activities, and is leading the implementation of scale up plans designed to achieve commercial manufacturing capability. Mr. Bassett is responsible for process development activities including leading Adaptimmune’s T-cell and lentivirus process development.

Please click on the link below to download the full Press Release:-

Adaptimmune Announces New Additions to Manufacturing Senior Management

Adaptimmune Expands T-cell Engineering Expertise to Develop Affinity Enhanced T-cell Therapies for Autoimmune Indications

7 January 2016

Adaptimmune Therapeutics plc (NASDAQ: ADAP), today announced that it is expanding its T-cell therapy development activities to target certain autoimmune diseases. Professor P. Julian Dyson, Ph.D. has joined the company as the head of the Autoimmune Group with responsibility for leading the autoimmune expansion, including the identification and validation of targets, and preclinical assessment of enhanced affinity TCRs directed against autoimmune targets.

“Professor Dyson is a luminary in the field of immune response regulation and, as such, is ideal to lead our expansion into autoimmune disease,” said James Noble, Chief Executive Officer. “He brings decades of research experience focused on the implication of T-cells in autoimmune diseases, and I would like to welcome him to the Adaptimmune team.”

Professor Julian Dyson joins Adaptimmune as Head of the new Autoimmune Group at the company’s research laboratories in Oxfordshire, U.K., with responsibility for leading the development of T-cell immunotherapy for autoimmune indications/conditions. Prof. Dyson brings 28 years of research experience in immunology working at the Medical Research Council and, since 2007, as Professor of Immunology at Imperial College London.

Please click on the link below to download the full Press Release:-

Adaptimmune Expands T-cell Engineering Expertise to Develop Affinity Enhanced T-cell Therapies for Autoimmune Indications

Adaptimmune Announces Initiation of Study to Evaluate its New Affinity Enhanced T-Cell Therapy Targeting MAGE-A10 in Patients with NSCLC, the Most Common Form of Lung Cancer

17 December 2015

Adaptimmune Therapeutics plc (Nasdaq: ADAP), today announced that it has initiated a Phase I/II study of its affinity enhanced T-cell therapy targeting the MAGE-A10 cancer antigen in patients with locally advanced or metastatic (Stage IIIb or IV) non-small cell lung cancer (NSCLC), the most prevalent type of lung cancer representing approximately 85 percent of lung cancers.

This will be the first study of Adaptimmune’s unpartnered affinity enhanced T-cell therapy targeting MAGE-A10, a highly immunogenic member of the MAGE-A family of cancer testis antigens. MAGE-A10 is expressed in a number of solid tumor cell types, and the immunogenicity of the MAGE-A10 antigen has been robustly established. Cancer testis antigen expression in cancer is often associated with higher grade tumors.

Please click on the link below to download the full Press Release:-

Adaptimmune Announces Initiation of Study to Evaluate its New Affinity Enhanced T-Cell Therapy Targeting MAGE-A10 in Patients with NSCLC, the Most Common Form of Lung Cancer